Novartis Gains Rights To Two Oral Targeted Investigational Therapies Focusing On P...
Novartis has gained exclusive rights to two oral targeted investigational therapies for patients with a range of life-threatening blood disorders and cancers that currently do not have effe...
Medical News Today,
Sat Nov 28 03:35:35 PST 2009
• Found on Yahoo! News
Micromet Enters Into Agreement With Lonza for the Manufacture of Blinatumomab
BETHESDA, Md -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced that ...
dBusinessNews.com,
Fri Nov 27 09:30:34 PST 2009
• Found on Yahoo! News
Topix.net
360,000 news channels, from Autos to your ZIP code.
• Found on Topix News
ASH Honors Rep. Doris O. Matsui (D-CA) And Melanie Bloom For Their Public Service,...
The American Society of Hematology (ASH), the world's largest professional society of blood specialists, will recognize a member of the U.S. House of Representatives and the national spokes...
Medical News Today,
Thu Nov 26 07:35:15 PST 2009
• Found on Yahoo! News
Gloucester Pharmaceuticals To Present Positive Results From Multiple Studies Of IS...
Gloucester Pharmaceuticals announced multiple presentations from clinical and preclinical studies of ISTODAX® (romidepsin) at the upcoming 51st American Society of Hematology (ASH) Annual M...
Medical News Today,
Wed Nov 25 21:35:39 PST 2009
• Found on Yahoo! News
ASH Honors Rep. Doris O. Matsui (D-CA) and Melanie Bloom for Their Public Service,...
WASHINGTON, Nov. 25 /PRNewswire-USNewswire/ -- The American Society of Hematology (ASH), the world's largest professional society of blood specialists, will recognize a member of the U.S.
redOrbit,
Wed Nov 25 11:08:00 PST 2009
• Found on Yahoo! News
(AFX UK Focus) 2009-11-25 15:44 UPDATE 3-Novartis strikes licensing deal with Incy...
ZURICH, Nov 25 (Reuters) - Swiss drugmaker Novartis has struck a licensing deal with Incyte Corp , paying $150 million up front for access to therapies to treat patients with life-threateni...
Interactive Investor,
Wed Nov 25 08:11:59 PST 2009
• Found on Yahoo! News
(AFX UK Focus) 2009-11-25 11:35 UPDATE 2-Novartis strikes licensing deal with Incy...
ZURICH, Nov 25 (Reuters) - Swiss drugmaker Novartis has struck a licensing deal with Incyte Corp, paying $150 million up front for access to therapies to treat patients with life-threatenin...
Interactive Investor,
Wed Nov 25 03:58:21 PST 2009
• Found on Yahoo! News
Press Release
Gloucester Pharmaceuticals today announced multiple presentations from clinical and preclinical studies of ISTODAX® (romidepsin) at the upcoming 51st American Society of Hematology (ASH) An...
PharmiWeb,
Wed Nov 25 01:55:57 PST 2009
• Found on Yahoo! News
ASH Honors Rep. Doris O. Matsui (D-CA) and Melanie Bloom for Their Public Service,...
WASHINGTON, Nov. 25 /PRNewswire-USNewswire/ -- The American Society of Hematology (ASH), the world's largest professional society of blood specialists, will recognize a member of the U.S. H...
PR Newswire via Yahoo! News,
Wed Nov 25 06:59:00 PST 2009
• Found on Yahoo! News
Multiple presentations from clinical and preclinical studies of ISTODAX to be pres...
Gloucester Pharmaceuticals today announced multiple presentations from clinical and preclinical studies of ISTODAX® (romidepsin) at the upcoming 51st American Society of Hematology (ASH) An...
News-Medical-Net,
Tue Nov 24 23:54:41 PST 2009
• Found on Yahoo! News
(AFX UK Focus) 2009-11-25 07:25 Swiss stocks - Factors to watch on Nov 25
ZURICH, Nov 25 (Reuters) - Swiss shares were seen opening higher on Wednesday after U.S. and Asian stocks climbed after the Federal Reserve raised U.S. growth forecasts for 2010.
Interactive Investor,
Tue Nov 24 23:42:42 PST 2009
• Found on Yahoo! News
Incyte Corporation - Pharmaceuticals & Healthcare - Deals And Alliances Profile - ...
Incyte Corporation (Incyte) is engaged in discovery and development of small molecule drugs to treat serious unmet medical needs in the field of oncology, inflammation, diabetes and human i...
OfficialWire,
Mon Nov 23 04:42:17 PST 2009
• Found on Yahoo! News
Gloucester Pharmaceuticals to Present Positive Results from Multiple Studies of IS...
CAMBRIDGE, Mass.----Gloucester Pharmaceuticals today announced multiple presentations from clinical and preclinical studies of ISTODAX® at the upcoming 51st American Society of Hematology A...
Business Wire via Yahoo! Finance,
Tue Nov 24 12:15:00 PST 2009
• Found on Yahoo! News
BioTime, Inc. Announces Third Quarter 2009 Financial Results and Update on Recent ...
ALAMEDA, Calif.----BioTime, Inc. reported financial results for the quarter ended September 30, 2009 and an update.
Business Wire via Yahoo! Finance,
Tue Nov 24 12:56:00 PST 2009
• Found on Yahoo! News
Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at th...
ARIAD Pharmaceuticals, Inc. today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 ...
News-Medical-Net,
Mon Nov 23 05:24:33 PST 2009
• Found on Yahoo! News
ARIAD to Present Data on Pan-BCR-ABL Inhibitor AP24534 at 51st American Society of...
CAMBRIDGE, Mass.----ARIAD Pharmaceuticals, Inc. today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present ...
Business Wire via Yahoo! Finance,
Mon Nov 23 04:35:00 PST 2009
• Found on Yahoo! News
Micromet Enters Into Agreement With Lonza for the Manufacture of Blinatumomab
BETHESDA, Md -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced that ...
dBusinessNews.com,
Wed Nov 25 14:43:14 PST 2009
• Found on Yahoo! News
Incyte Corporation - Pharmaceuticals & Healthcare - Deals And Alliances Profile - ...
Incyte Corporation (Incyte) is engaged in discovery and development of small molecule drugs to treat serious unmet medical needs in the field of oncology, inflammation, diabetes and human i...
OfficialWire,
Mon Nov 23 04:41:18 PST 2009
• Found on Yahoo! News
Micromet Enters Into Agreement With Lonza for the Manufacture of Blinatumomab
BETHESDA, Md. -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced that...
GlobeNewswire via Yahoo! Finance,
Tue Nov 24 04:00:00 PST 2009
• Found on Yahoo! News